Mauricio Cuello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mauricio Cuello has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Gabriel Krygier
Prof. Titular del Servicio de Oncología Clínica, Hospital de Clínicas, Facultad de Medicina, Universidad de la República. Uruguay
2 shared publications Alex Makhnin
Memorial Sloan Kettering Cancer Center, New York, New York
1 shared publicationAna Marin
University of Granada, Quantitative Methods for the Economics and Enterprise, Granada, Spain
1 shared publicationAndrea Farina
Memorial Sloan Kettering Cancer Center, New York, New York
1 shared publication- Andres Felipe Cardona
Direction of Research, Science, and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia
1 shared publication Andrés Martinez
Memorial Sloan Kettering Cancer Center, New York, New York
1 shared publication
Latest Publications
- Open Access
- 27 May 2026
- Published by Sociedad Medicina Interna de Uruguay in INNOTEC
- Vol. 11, e301
Efectos adversos inmunomediados en pacientes portadores de tumores sólidos tratados con bloqueadores de puntos de control inmunológico en cuatro centros de Montevideo, Uruguay
Introducción: La inmunoterapia es una estrategia clave en la terapia oncológica actual y sus indicaciones con fines curativos o paliativos siguen creciendo. Su objetivo es fortalecer la respuesta inmune efectora contra las células tumorales con un perfil de efectos adversos diferente al de los tratamientos convencionales. En este trabajo evaluamos el perfil y la frecuencia de efectos adversos inmunomediados de los inhibidores de puntos de control inmunológico (ICI), en pacientes de 4 instituciones de Montevideo. Metodología: Estudio observacional, descriptivo, transversal y retrospectivo. Se analizaron los datos de pacientes portadores de tumores sólidos que recibieron tratamiento con inhibidores del punto de control inmunológico en cuatro centros asistenciales de Montevideo, Uruguay, en el periodo comprendido entre 2021-2024. Resultados: El 49,5% (n=47) de los pacientes tratados en monodroga (ICI, ICI+ICI) presentaron efectos adversos, 64,3% (n=9) de aquellos tratados con ICI en combinación con ITK y 67,4% (n=33) de quienes recibieron ICI en combinación con QT. En términos generales, el estudio evidenció que la población se comporta de forma similar a los registros publicados. Conclusiones: El creciente uso de los inhibidores de punto de control inmune (inmunoterapia) en el tratamiento del cáncer, trae aparejado la aparición de un nuevo tipo de efectos adversos, conocidos como efectos adversos inmuno relacionados o irAEs. En este trabajo se reportaron los efectos adversos vinculados al tratamiento con inmunoterapia en cuatro centros de Montevideo, Uruguay. El porcentaje de irAEs descrito en este estudio coincide con los reportados en los ensayos clínicos y revisiones sobre el tema.
- 27 May 2026
- Published by Sociedad Medicina Interna de Uruguay in INNOTEC
- Vol. 11, e301
Open AccessEfectos adversos inmunomediados en pacientes portadores de tumores sólidos tratados con bloqueadores de puntos de control inmunológico en cuatro centros de Montevideo, Uruguay
Introducción: La inmunoterapia es una estrategia clave en la terapia oncológica actual y sus indicaciones con fines curativos o paliativos siguen creciendo. Su objetivo es fortalecer la respuesta inmune efectora contra las células tumorales con un perfil de efectos adversos diferente al de los tratamientos convencionales. En este trabajo evaluamos el perfil y la frecuencia de efectos adversos inmunomediados de los inhibidores de puntos de control inmunológico (ICI), en pacientes de 4 instituciones de Montevideo. Metodología: Estudio observacional, descriptivo, transversal y retrospectivo. Se analizaron los datos de pacientes portadores de tumores sólidos que recibieron tratamiento con inhibidores del punto de control inmunológico en cuatro centros asistenciales de Montevideo, Uruguay, en el periodo comprendido entre 2021-2024. Resultados: El 49,5% (n=47) de los pacientes tratados en monodroga (ICI, ICI+ICI) presentaron efectos adversos, 64,3% (n=9) de aquellos tratados con ICI en combinación con ITK y 67,4% (n=33) de quienes recibieron ICI en combinación con QT. En términos generales, el estudio evidenció que la población se comporta de forma similar a los registros publicados. Conclusiones: El creciente uso de los inhibidores de punto de control inmune (inmunoterapia) en el tratamiento del cáncer, trae aparejado la aparición de un nuevo tipo de efectos adversos, conocidos como efectos adversos inmuno relacionados o irAEs. En este trabajo se reportaron los efectos adversos vinculados al tratamiento con inmunoterapia en cuatro centros de Montevideo, Uruguay. El porcentaje de irAEs descrito en este estudio coincide con los reportados en los ensayos clínicos y revisiones sobre el tema.
- 19 March 2024
- Published by Elsevier in Journal of Cancer Policy
- Vol. 40, 100472
Socioeconomic disparities and health literacy: Unraveling the impact on diagnostic and cancer care in Uruguay
- 19 March 2024
- Published by Elsevier in Journal of Cancer Policy
- Vol. 40, 100472
Socioeconomic disparities and health literacy: Unraveling the impact on diagnostic and cancer care in Uruguay
- Open Access
- 1 August 2023
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 14 (4) , 300-308
Assessing Adherence to Adjuvant Hormone Therapy in Breast Cancer Patients in Routine Clinical Practice
Assessing Adherence to Adjuvant Hormone Therapy in Breast Cancer Patients in Routine Clinical Practice
- 1 August 2023
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 14 (4) , 300-308
Open AccessAssessing Adherence to Adjuvant Hormone Therapy in Breast Cancer Patients in Routine Clinical Practice
Assessing Adherence to Adjuvant Hormone Therapy in Breast Cancer Patients in Routine Clinical Practice
- 1 March 2022
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 24 (3) , 189-204
Multiplex SuperSelective PCR Assays for the Detection and Quantitation of Rare Somatic Mutations in Liquid Biopsies
- 1 March 2022
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 24 (3) , 189-204
Multiplex SuperSelective PCR Assays for the Detection and Quantitation of Rare Somatic Mutations in Liquid Biopsies
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e97
Synchronous colorectal cancer: incidence and epidemiological features in a Uruguayan cohort.
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e97
Synchronous colorectal cancer: incidence and epidemiological features in a Uruguayan cohort.
- Open Access
- 18 May 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0154293
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. The primary endpoints were the overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). A cohort of 144 patients were administered pemetrexed (500 mg/m2), carboplatin (AUC, 5.0 mg/ml/min) and bevacizumab (7.5 mg/kg) intravenously every three weeks for up to four cycles. Maintenance PB was administered until disease progression or unacceptable toxicity. One hundred forty-four Colombian patients with a median follow-up of 13.8 months and a median number of 6 maintenance cycles (range, 1–32) were assessed. The ORR among the patients was 66% (95% CI, 47% to 79%). The median PFS and (OS) rates were 7.9 months (95% CI, 5.9–10.0 months) and 21.4 months (95% CI, 18.3 to 24.4 months), respectively. We documented grade 3/4 hematologic toxicities, including anemia (14%), neutropenia (8%), and thrombocytopenia (16%). The identified grade 3/4 non-hematologic toxicities were proteinuria (2%), venous thrombosis (4%), fatigue (11%), infection (6%), nephrotoxicity (2%), and sensory neuropathy (4%). No grade >3 hemorrhagic events or hypertension cases were reported. OS was significantly higher in patients with the lowest TS mRNA levels [median, 29.6 months (95% CI, 26.2–32.9)] compared with those in patients with higher levels [median, 9.3 months (95% CI, 6.6–12.0); p = 0.0001]. TS expression (mRNA levels or protein expression) did not influence the treatment response. Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. This regimen was associated with acceptable toxicity and prolonged OS, particularly in patients with low TS expression. We found a role for Ki67 and TS expression as prognostic factors.
- 18 May 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0154293
Open AccessPemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. The primary endpoints were the overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). A cohort of 144 patients were administered pemetrexed (500 mg/m2), carboplatin (AUC, 5.0 mg/ml/min) and bevacizumab (7.5 mg/kg) intravenously every three weeks for up to four cycles. Maintenance PB was administered until disease progression or unacceptable toxicity. One hundred forty-four Colombian patients with a median follow-up of 13.8 months and a median number of 6 maintenance cycles (range, 1–32) were assessed. The ORR among the patients was 66% (95% CI, 47% to 79%). The median PFS and (OS) rates were 7.9 months (95% CI, 5.9–10.0 months) and 21.4 months (95% CI, 18.3 to 24.4 months), respectively. We documented grade 3/4 hematologic toxicities, including anemia (14%), neutropenia (8%), and thrombocytopenia (16%). The identified grade 3/4 non-hematologic toxicities were proteinuria (2%), venous thrombosis (4%), fatigue (11%), infection (6%), nephrotoxicity (2%), and sensory neuropathy (4%). No grade >3 hemorrhagic events or hypertension cases were reported. OS was significantly higher in patients with the lowest TS mRNA levels [median, 29.6 months (95% CI, 26.2–32.9)] compared with those in patients with higher levels [median, 9.3 months (95% CI, 6.6–12.0); p = 0.0001]. TS expression (mRNA levels or protein expression) did not influence the treatment response. Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. This regimen was associated with acceptable toxicity and prolonged OS, particularly in patients with low TS expression. We found a role for Ki67 and TS expression as prognostic factors.